Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting

Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting 02.06.2023 / 08:00 CET/CEST MEDIA RELEASE

Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

For information on the agenda items and proposals of the board of directors as well as on how to attend the 2023 Annual General Meeting, exercise voting rights or issue voting instructions to the independent proxy, shareholders can access the invitation to the 2023 Annual General Meeting at https://ir.kinarus.com/2023-agm/.

The annual report for the financial year 2022, including the management report, the statutory financial statements, the consolidated financial statements, the auditors' report and the compensation report can be downloaded from the Company’s website: https://ir.kinarus.com/financial-reporting/.

The 2023 Annual General Meeting will be conducted in English. A record of the resolutions taken by the 2023 Annual General Meeting will be available after the 2023 Annual General Meeting on the Company’s website at https://ir.kinarus.com/2023-agm/.

Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its knowledge and drug development competencies to in-license and develop mid-stage clinical assets in which they have identified an increased probability of clinical and regulatory success and a rapid path to market. Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Contacts
 

Kinarus Therapeutics Holding AG Hochbergerstrasse 60C 4057 Basel, Switzerland [phone] [e-mail]

Investors & Media Chris Maggos Cohesion Bureau [phone] [e-mail]

 

Legal disclaimer

THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL NOR AN INTIMATION TO SUBMIT A PROPOSAL FOR THE ACQUISITION OF SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN ANY JURISDICTION WHERE IT IS UNLAWFUL TO BE DISTRIBUTED.

---

End of Media Release

---

1647793  02.06.2023 CET/CEST

The Perfect Holding Stock at the time of publication of the news with a fall of -3,33 % to 0,012CHF on SIX Swiss (CHF) stock exchange (01. Juni 2023, 17:30 Uhr).